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Common Variable Immunodeficiency (CVID) is characterized by impaired antibody
production and poor terminal differentiation of the B cell compartment, yet its
pathogenesis is still poorly understood. We first reported the occurrence of epigenetic
alterations in CVID by high-throughput methylation analysis in CVID-discordant
monozygotic twins. Data from a recent whole DNA methylome analysis throughout
different stages of normal B cell differentiation allowed us to design a new experimental
approach. We selected CpG sites for analysis based on two criteria: one, CpGs with
potential association with the transcriptional status of relevant genes for B cell activation
and differentiation; and two, CpGs that undergo significant demethylation from naïve
to memory B cells in healthy individuals. DNA methylation was analyzed by bisulfite
pyrosequencing of specific CpG sites in sorted naïve and memory B cell subsets from
CVID patients and healthy donors. We observed impaired demethylation in two thirds
of the selected CpGs in CVID memory B cells, in genes that govern B cell-specific
processes or participate in B cell signaling. The degree of demethylation impairment
associated with the extent of the memory B cell reduction. The impaired demethylation
in such functionally relevant genes as AICDA in switchedmemory B cells correlated with a
lower proliferative rate. Our new results reinforce the hypothesis of altered demethylation
during B cell differentiation as a contributing pathogenic mechanism to the impairment
of B cell function and maturation in CVID. In particular, deregulated epigenetic control of
AICDA could play a role in the defective establishment of a post-germinal center B cell
compartment in CVID.
Keywords: common variable immunodeficiency, B cells, CpG, DNA methylation, B cell phenotype, proliferation
rate
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KEY POINTS
• B cell key genes display defective demethylation in selected
CpG sites in the transition from naïve to switched memory
B cells in CVID, which might contribute to terminal B
cell defects.
• Impaired demethylation is associated with the reduction of
memory B cells in CVID patients.
INTRODUCTION
Common Variable Immunodeficiency (CVID) comprises a
group of primary syndromes of antibody deficiencies and
constitutes the most frequent type of symptomatic primary
immunodeficiency (PID), and yet it is not very well-understood.
CVID patients are characterized by markedly decreased
IgG with IgA, IgM, or both, defective specific antibody
formation or decreased memory B cell counts. The majority
of patients suffer recurrent bacterial infections, and many
present severe complications such as autoimmune cytopenias,
lymphoproliferative disorders, enteropathy, and malignancies,
which suggests profound immune deregulation (1). All CVID
patients present some degree of impaired differentiation of the
B cell compartment, mostly normal percentage of circulating
B cells, but markedly reduced memory B cells and absent
plasma cells (2). Maturation and terminal specialization of B
cells require the integration of molecular signals, driven by
transcription factors and consolidated by epigenetic marks,
which lead to initiation and maintenance of stage-dependent
transcriptional programs (3). The epigenome refers to heritable
modifications that influence gene expression but do not change
the DNA sequence, such as DNA methylation and histone
modifications (3, 4). DNA methylation consists of the addition
of a methyl group to the 5′ position of a cytosine followed by
a guanine, known as CpG dinucleotides. This modification is
mediated by enzymes of the DNA methyltransferase (DNMT)
family (5, 6). In some cases, CpG dinucleotides are clustered
in regions termed CpG islands, many of which are located
near gene promoters and their methylation generally associates
with gene silencing. In contrast, isolated CpGs associate with
different expression outcomes depending on their genomic
location and chromatin context (3). The epigenome of B cells is
dynamic, and it changes during differentiation. During the early
steps of B cell differentiation in bone marrow, profound DNA
demethylation is associated with the expression of B-specific
lineage transcription factors such as E2A, EBF, and Pax5 (7–9).
Upon antigen encounter, peripheral mature B cells undergo the
germinal center (GC) reaction, in which somatic hypermutation
(SHM) and class switch recombination (CSR) occurs. These
processes are associated with a high replication rate and extensive
demethylation (6, 10, 11). Finally DNA methylation changes
are required for the establishment of long-lived memory and
plasma B cells, which are essential for the maintenance of specific
antigen responses (12–14).
CVID is mostly sporadic and the onset can occur at any
age, with increased incidence at early adulthood. Progressive
immunological deterioration can be traced occasionally
before diagnosis is established. Isolated IgA deficiency can
coexist in families with CVID members, and progression
from one disease to another has been described. The
general consensus is that CVID pathogenesis is complex
and multifactorial, and only in 10–15% of the cases appears to
be associated with a monogenic defect (15). Several genes
harboring pathogenic or predisposing mutations have
been associated with CVID, altering signaling pathways or
molecular events relevant for B cell function and antibody
formation. Initially, these genes include CD19 (16), CD20
(17), CD21 (18), CD81 (19), ICOS (20), TACI (21), BAFFR
(22), however, recently more genes have been associated
with CVID such as TWEAK, CD27, IL21, IL21R, LRBA,
CTLA4, PI3KCD, IKAROS, NFKB1, NFKB2, PRKCD, PIK3R1,
VAV1, RAC2, BLK, and IRF2BP2 (23–25). Although new
predisposing genes will surely be identified, it seems unlikely
that a yet unknown single gene defect could account for
the etiology of the genetically undiagnosed CVID patients.
Therefore, although a predisposing genetic background
seems plausible, immunological and clinical penetrance could
depend on additional pathogenic mechanisms in most CVID
patients (15).
The uncommon epidemiology and complex pathogenesis of
CVID led us to explore new mechanisms that could impair
relevant gene expression for terminal B cell function, other
than in-born variations in DNA sequence. In a previous
study (26), we reported, for the first time, the existence
of aberrant DNA methylation in CVID B cells. Specifically,
high-throughput DNA methylation analysis in B cells from
a pair of CVID discordant monozygotic twins revealed a
predominant impairment of DNA demethylation in critical
genes for B cell biology. In addition, analysis of the DNA
methylation profiles of sorted naïve, unswitched and switched
memory B cells from a cohort of CVID patients revealed
impaired DNA demethylation during naïve to memory B
cell transition.
The most comprehensive study of DNA methylome variation
during physiological human B cell maturation has recently been
published by Kulis et al. (27), who, performing whole-genome
bisulfite sequencing (WGBS) analysis, generated unbiased
methylation maps of several sorted subpopulations spanning the
entire B cell differentiation pathway in healthy individuals.
In this work, we expand our initial observation, and provide
stronger evidence, by focusing our analysis on selected CpG
sites near transcription start sites of genes that are relevant
for late B cell differentiation. These CpG sites were selected
from the study by Kulis et al. (27), and displayed significant
demethylation in memory B cells compared to naïve B cells from
healthy individuals. The list of genes includemembrane receptors
promoting survival, signaling mediators for cycle progression,
activators of transcription factors, and genes involved in
CSR and SHM. By using this approach, we confirmed the
impaired demethylation in CVID memory B cells for most
of the CpG sites analyzed. Our new results reinforce the
hypothesis of a defective demethylation that associates with
the functional and maturational impairment of memory B cells
in CVID.
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MATERIALS AND METHODS
Patient Clinical and Immunological Study
Peripheral blood was obtained from 23 CVID patients (according
to ESID criteria) and 17 healthy donors at La Paz University
Hospital, after informed consent was obtained. The study was
approved by the Ethics Committee of the Hospital, and adhered
to the principles of the Declaration of Helsinki. Clinical data were
obtained from hospital records.
B cell phenotype was performed staining whole blood with
CD19 Percp Cy5.5, CD27 FITC, CD38 FITC (BD Biosciences)
IgM Alexa Fluor 647 (Jackson Inmuno Research), and IgD PE
(Southern Biotech) antibodies and analyzed on a FACS Canto
flow cytometer (BD Biosciences).
Peripheral blood mononuclear cells (PBMCs) were obtained
after Ficoll gradient centrifugation. Naïve (CD19+IgD+CD27−),
unswitched memory USm (CD19+IgD+CD27+) and switched
memory Sm (CD19+IgD−CD27+) B cells were sorted from
viable PBMCs after staining with CD19 FITC (4G7BD), Ig D
PE (Southern Biotech), CD27 BV421 (M-T271, BD) antibodies
in a FACS Aria (BD Biosciences). Purity was confirmed to be
>95% for selected fractions. Sorted cells were pelleted and stored
at −80◦C. Further details of the sorting strategy are depicted in
Supplementary Figure 1.
Candidate CpGs and Gene Selection for
Methylation Analysis
We obtained the raw data available from the methylome analysis
performed on several B cell subpopulations by Kulis et al.
(27). We selected CpGs located at the promoter regions of
several genes relevant for the B cell biology for analysis based
on strict criteria: > 25% of difference in methylation in naïve
(CD19+IgD+CD27−) vs. memory B cells (CD19+CD27+ IgA+
or IgG+). We considered a CpG site to be hypomethylated status
when <0.5-fold was observed in the transition from naive to
switch memory B cells. To increase the potential influence of
selected CpGs on the transcriptional activity of the nearby genes,
we included an extra requirement the proximity to at least two
other CpGs with similar requisites for their methylation status in
näive and memory B cells. We used the UCSC Genome Browser
database (GRCh 37/hg 19) to precisely define the location of a
given CpGs site to nearby genes (Supplementary Figure 2).
We selected nine CpG sites at the promoters of nine
functionally relevant B cell genes (AKT, TNFRSF13C, AICDA,
BCL-6, BCL-10, FOXO1, MALT1, NFKB2, and STAT3)
(Supplementary Table 1 and Supplementary Figure 2). Each
CpG was interrogated for its methylation status in sorted cell
fractions of naïve, unswitched and switched memory B cells from
CVID patients and healthy donors.
Bisulfite-Modified DNA Pyrosequencing
We extracted DNA with All prep DNA/RNA micro kit (Qiagen)
and bisulfite-converted using the EZ-96 DNA methylation kit
(Zymo Research, Orange, CA, USA). We generated biotinylated
amplicons for each CpG with specific primers (Sigma Aldrich)
by PCR using the Immolase DNA polymerase (Bioline). Primers
were designed with the PyroMark Assay Design Software (Qiagen
version 2.0.01.15) (Supplementary Table 2). Pyrosequencing
reactions were performed and DNA methylation quantified on
a Pyromark Q96 MDsystem (Qiagen). Results from bisulfite
pyrosequencing are presented as the percentage of methylation.
KRECs and Igκ REHMA Assay
We inferred the replication history of naïve, unswitched and
switched memory B cells from the same patients and healthy
controls than in the DNA methylation study. To this end, we
used the κ–deleting recombination excision circle (KREC) assay,
as described by van Zelm et al. (28). The replication history is
estimated by the ratio between genomic coding joints and signal
joints on KRECs of the Igκ intron RSS-K deleting rearrangement,
quantified by Real Time PCR using specific primers and probes
(28), applying the 1CT sample= Ct (signal joint)–Ct (coding
joint) formula. The differences in Ct values is a measure for the
number of cell divisions in B cells subsets that have undergone
on average.
The extension of somatic hypermutation (SHM) in the
memory B cell subset was measured using the Igκ-restriction
enzyme hot spot mutation assay (IgκREHMA). This method
described by van Zelm et al. (28) analyses the percentage of
rearranged Vκ3-20 (VκA27) gene segments that contain somatic
hypermutations in a specific sequence motif. Briefly, a PCR was
performed on genomic DNA using an HEX-coupled Vκ3-20
intron forward primer and 2 FAM-coupled Jκreverse primers
recognizing all 5 Jκ gene segments. PCR products of 500 bp
were digested by restriction enzymes Fnu4HI and Kpn1, and
the digested products run on an ABI 3130xl capillary sequencer
(Applied Biosystems). Mutated gene products containing SHM
generate 262 bp fragments, whereas unmutated 244 or 247
fragments. To assess the percentage of mutated alleles the
calculation is:
%mutates alleles =
peak height mutated fragment (262 pb)
peak height unmutated fragments (244 and 247 bp)
Statistical Analysis
The methylation status in B cell subsets from CVID patients
and controls was analyzed and graphs were created with the
GraphPadPrism 6.0 Software (GraphPad software, San Diego,
California, USA). Two group comparisons were performed using
Mann Whitney test, and Spearman’s coefficient was used to
determine correlation. Statistically significant was considered
with p < 0.05 (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001;
∗∗∗∗p < 0.0001).
RESULTS
Methylation Status of CpG Sites Near
Promoters of Key B Cell Genes in CVID
In order to reassess and accumulate supportive data for
the potential pathogenic relevance of impaired DNA
demethylation in the generation or maintenance of the
memory B cell compartment in most CVID patients (26),
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we applied an experimental strategy based on the analysis
of selected CpGs sites with significantly differential DNA
methylation in memory compared with naïve B cells in
healthy individuals (27) (see Methods). The precise genomic
location of those CpGs in relation to the nearest gene is
depicted in Supplementary Figure 2 and their methylation
status in the WGBS data from Kulis et al. is compiled in
Supplementary Table 1.
All selected CpG sites had lower levels of DNAmethylation in
memory B cells compared to naïve B cells in healthy donors, and
were located at critical genes involved in B cell differentiation and
activation (AKT1, FOXO1) (29–33), NF-κB dependent regulation
of B cell survival (BCL-10, MALT1, NFKB2) (34–36), JAK/STAT
signaling (STAT3) (37, 38), B cell survival receptors (BAFF-R)
(39, 40), CSR, SHM, and GC reaction (AICDA, BCL-6) (41–44)
(Supplementary Figure 3).
We determined the DNA methylation levels of
the aforementioned CpG sites in sorted fractions
of naïve (CD19+IgD+CD27−), unswitched memory
(CD19+IgD+CD27+) and switched memory
(CD19+IgD−CD27+) B cells from a total of 23 CVID
patients and 17 healthy donors by pyrosequencing of
bisulfite-modified DNA.
Our analysis confirmed previous data by Kulis et al. (27)
as all selected CpGs had higher levels of methylation in
naïve B cells than class-switched memory B cells in healthy
individuals (Figure 1). For unswitched memory B cells, the
methylation levels for the selected CpGs were between naïve and
switched memory B cells, supporting previous observations (45).
Unswitchedmemory B cells expressing surface IgM can represent
either alternative memory B cell differentiated from naïve B cells
or initial stages in memory B cell differentiation. Furthermore,
unswitched memory B cells can be generated both in a germinal
center-independent and dependent reaction (46–48).
For all but one selected CpGs, CVID naïve B cells
presented similar levels of methylation to healthy controls
(Figure 1). Specifically, the CpG site at the FOXO 1 gene
displayed a significant decreased mean level of methylation
in naïve B cells from CVID patients compared with controls
(p= 0.0006; Figure 1).
The analysis of the methylation status of the selected CpG
sites in memory B cells from CVID patients revealed three major
different patterns. First, defective demethylation in switched
memory B cells from CVID patients were observed compared
with healthy counterparts (Figure 1). This pattern was observed
in CpG sites at the AICDA, BCL-6, and AKT1 genes, which, in
switched memory B cells, displayed higher methylation in CVID
patients compared with healthy donors (p < 0.0001, p = 0.0010,
and p = 0.0024, respectively). Interestingly, although the CpG
site at the FOXO1 gene was hypomethylated in CVID naïve
B cells, CVID switched memory B cells presented significantly
higher methylation with respect to control (p < 0.0001). Second,
defective demethylation was observed in both unswitched and
switched memory B cells from CVID patients compared with
healthy controls (Figure 1). This pattern was observed for the
selected CpG at the NFKB2 gene (p = 0.0317 and p = 0.0122,
respectively). For the CpG site at the STAT3 promoter, CVID
unswitched memory B cells showed increased mean levels of
methylation in comparison to healthy donors (p = 0.0183).
Switched memory B cells presented dispersed methylation levels
in the CpG at STAT3 among CVID, with strikingly high levels
of methylation in a subgroup of patients. Third, CpGs at the
MALT1, BCL-10, and BAFF-R genes did not show significant
differences neither in CVID unswitched memory nor in switched
memory B cells (Figure 1) as compared to controls.
Therefore, impaired demethylation is predominantly
observed in switched memory B cells from CVID, but is not a
general phenomenon for all interrogated CpGs.
Impairment of DNA Demethylation
Associates With B Cell Phenotype in CVID
Patients
We next explored whether the impaired demethylation observed
in selected CpGs present any correlation with the decreased
numbers of unswitched and switched memory B cells in CVID
patients. The reduction of memory B cells has been recently
accepted as one of the diagnosis criteria for CVID. In the
Euroclass trial (2) normal ranges for percentages of unswitched
memory (7.2–30.8%) and switched memory (6.5–29.2%) B cells
were established. Based on that strategy, we sub-classified our
cohort of patients into three subgroups: CVID patients with
normal numbers of unswitched (USm) and switched (Sm)
memory B cells; CVID patients with normal numbers of
unswitched (USm) memory B cells but reduced switched (Sm)
memory B cells; and CVID patients with reduced numbers
of both unswitched (USm) and switched (Sm) memory B
cells. To analyze a possible relationship between the increased
methylation of some CpGs and the number of memory B cells, we
represented the results of those CpGs which showed significantly
higher methylation levels in CVID memory B cells, but in
this case subdividing patients according to the memory B cell
phenotype (Figure 2).
Interestingly, CVID patients with normal percentages of
unswitched memory and switched memory B cells had similar
methylation levels than healthy counterparts for CpGs at the
AICDA, FOXO, AKT1, NFKB2, and STAT3 genes, in which
these CpGs underwent demethylation to a similar extent to
B cells from healthy individuals. The one exception was the
CpG site at the BCL-6 gene. This might suggest that impaired
demethylation of BCL6 (Figure 2B) inmemory B cells could have
an impact in the later step of differentiation toward plasma cells, a
common feature to all CVID regardless the presence of switched
memory B cells.
In addition, subclassification according to B cell phenotype
revealed that patients with reduction of both unswitched and
switched memory B cell compartments presented statistically
significant hypermethylation of CpGs in AICDA and BCL6
in unswitched memory B cells (p = 0.0110 and p = 0.0469,
respectively; Figures 2A,B). These results suggest that defective
acquisition of epigenetic and transcriptional status of certain
B cell-specific genes, especially AICDA and BCL6, might be
associated with the failure to produce or maintain normal levels
of all type of memory and plasma B cells.
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FIGURE 1 | Percentage of DNA methylation obtained by pyrosequencing for the selected CpG in different genes, represented as box and whiskers, in the B cell
subsets naïve, unswitched (USm) and switched (Sm) memory B cells from healthy donors (in blue) and CVID patients (in red). Box represent mean with minimum to
maximum. P-value of statistically significant differences by Mann-Whitney test are included (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
As indicated above, only the CpG at the FOXO1 gene showed
differential methylation levels in CVID naïve B cells when
compared to healthy controls. In fact, according to the Euroclass
trial (2), a subgroup of patients displayed increased percentages
of transitional B cells that correlated with lymphoproliferative
complications. Hence, we reanalysed the methylation levels for
this CpG site in CVID patients based on the presence or absence
of transitional B cells, and found that average methylation at
this site in naïve B cells is significantly lower in patients without
increased transitional B cells (Figure 3C).
B Cell Proliferation Associates With
Defects in Acquiring Correct DNA
Methylation Changes
To identify possible factors along the B cell differentiation process
that could contribute to the impaired demethylation observed in
CVID memory B cells, we assessed the replication history, by
KREC assay (28), in sorted B cell subpopulations from CVID
patients and controls, utilizing the same DNA samples as the
methylation analysis.
When we compared the total number of cell divisions in the
different sorted B cells populations, we observed that naïve B
cells from CVID patients had experienced a significantly higher
number of divisions than those from healthy donors (p< 0.0001),
(Figure 3A). In contrast, there were no significant differences in
the accumulated number of B cell divisions in the unswitched
and switchedmemory B cells between CVID patients and healthy
controls. These results suggest that CVID B cells might have
experienced an extra rate of proliferation at the naïve stage,
perhaps rendering less cumulative opportunities for cell division
through the GC reaction.
We next evaluated if the impaired CpG demethylation
observed in CVID switched memory B cells could be related to
the proliferation rate. We did not observe a clear correlation in
healthy controls for the CpGs studied. However, a significant
negative correlation between higher methylation levels in
switched memory B cells and lower number of cell divisions
in switched memory B cells is observed in CVID patients
for CpGs at the AICDA (Spearman correlation = −0.8328,
p < 0.0001) gene (Figure 3B). Furthermore, this negative
correlation between the number of cell divisions and the
methylation level in AICDA is also observed in unswitched
memory B cells from CVID patients (Spearman correlation =
−0.5273, p= 0.203).
In addition, we also tested whether cell proliferation could be
playing a role in the decreased methylation levels of the CpG
site at the FOXO1 gene in naïve B cells from CVID patients
when compared to healthy controls. CVID patients without
increased transitional B cells, that also presented significantly
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FIGURE 2 | DNA methylation levels for the selected CpG in different genes, in the naïve, unswitched (USm) and switched (Sm) memory B cells represented as
percentage in box and whiskers. HD are represented in blue. CVID patients with normal numbers of unswitched (USm) and switched (Sm) memory B cells in red, CVID
patients with normal numbers of unswitched (USm) memory B cells but reduced switched (Sm) memory B cells in orange; in green CVID patients with reduced
numbers of both unswitched (USm) and switched (Sm) memory B cells. Box represent mean with minimum to maximum. The P-value is shown for the cases with a
statistically significant difference by Mann Whitney test (*p < 0.05; **p < 0.01; ***p < 0.001).
lowermethylation levels (Figure 3C), showed significantly higher
number of cells divisions in naïve B cells when compared with
normal controls and naïve B cells from CVID patients with
increased transitional B cells (Figure 3D).
Reduced Somatic Hypermutation (SHM) in
CVID Memory B Cells With
Hypermethylated AICDA
A major event in the late B cell differentiation is the
diversification of the GC response with the generation
of different immunoglobulin isotypes and subclasses
from the IgM+IgD+ naïve B cells through the class
switch recombination (CSR) and the maturation of
antigen affinity by somatic hypermutation (SHM). Both
processes depend on the crucial action of Activation-
Induced Cytidin Deaminase encoded by the AICDA
gene. AID is virtually not expressed in naïve B cells and
becomes upregulated upon B cell activation during the
GC reaction.
We perfomed IgκREHMA assay using the same DNA
samples obtained from sorted populations of naïve, unswitched
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FIGURE 3 | (A) Total number of cell divisions calculated by KREC assay, for the different B cell populations, naïve, unswitched (USm) and switched (Sm) memory B
cells in HD (blue) and CVID patients (red). (B) Correlation between numbers of cell divisions in switched memory (Sm) B cells and the corresponding percentage of
methylation of the selected CpG in AICDA in healthy donors (blue) and CVID patients (red). Spearman correlation test was used in CVID patients Spearman
coeficient= −0.8328, p < 0.0001, 95% confidence interval (−0.9377 to −0.5890) in HD Spearman coeficient= 0.3130, p = 0.2367, 95% confidence interval
(−0.2317 to 0.7082). (C) Box and whiskers showing the percentage of DNA methylation in naïve B cells obtained by pyrosequencing for the selected CpG in FOXO in
HD (blue), CVID without expansion of transitional B cells (red) and patients with >9% transitional B cells (green). (D) Total number of cell divisions calculated by KREC
assay in naïve B cells in HD (blue), CVID without expansion of transitional B cells (red) and patients with >9% transitional B cells (green). P-value of statistically
significant differences by Mann-Whitney test are included (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
and switched memory B cells from CVID patients and
controls. As expected, naïve B cells from both patients
and controls showed virtual absence of SHM. Remarkably,
SHM levels were significantly reduced in the unswitched
and switched memory B cell subpopulations from CVID
patients (p = 0.0004 and p = 0.0001, respectively) as
shown in Figure 4. Reduced demethylation of AICDA
in CVID individuals could be related to decreased
AID expression in GC B cells of CVID patients, and
subsequently contributing to decreased SHM in CVID
memory B cells.
DISCUSSION
Aberrant DNA methylation has recently been shown to be
a key feature in the deregulation of the B cell compartment
of CVID patients (26). In this study, we dissected the
divergent changes in DNA methylation of several relevant
CpGs in the B cell subpopulations of CVID, providing
further knowledge in understanding its etiology. We describe
how several CpG sites, whose methylation levels decrease
from naïve to memory B cells in healthy individuals (27),
located at regulatory elements from key genes of B cell
biology remain highly methylated in memory B cells from
CVID patients. Most importantly, the severe reduction of
memory B cells commonly seen in most CVID patients
relates to the degree of impairment of demethylation in some
genes, suggesting a role for their defective demethylation
FIGURE 4 | Frequency of SHM in naïve, unswitched (USm) and switched (Sm)
memory B cells in healthy donors (blue) and CVID patients (red). By definition,
naïve B cell do not undergo SHM, the frequency of SHM is severely reduced in
USm and Sm in CVID patients. The P-value is shown for comparisons
between HD and CVID patients with a statistically significant difference by
Mann-Whitney test (***p < 0.001). Box and whiskers with minimum to
maximum.
and the impaired generation of a competent memory B cell
compartment. These new data, obtained by an alternative
experimental approach to our original observation in a
pair of CVID discordant monozygotic twins (26), reinforces
the hypothesis that decreased demethylation is a possible
contributing mechanism to the impaired B cell maturation in
CVID patients.
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Many genetically defined CVID patients present mutations in
prototypical B cell genes, implying that intrinsic B cell defects
could account for CVID. Paradoxically, pathogenic single gene
variants seem to be only present in a minority of patients (15). B
cell differentiation is promoted by activation of transcriptional
programs governed by transcription factors and consolidated
by epigenetic marks. One of the best characterized is DNA
methylation, essential not only in B cells, but also in T cells,
to modulate transcriptional programs in response to antigens
as well as the acquisition of effector functions (49). DNA
methylation contributes to transcriptional regulation through
a number of mechanisms, including specific recruitment of
methyl-CpG binding domain proteins, that form part of large
chromatin remodeling complexes, and through the modulation
of transcription factors binding (50).
Extensive DNA methylome remodeling along B cell
development has been well-documented. At certain key
stages, demethylation plays a fundamental role. Early B cell
progenitors experience DNA demethylation concurrently with
an increase in expression of essential transcription factors E2A,
EBF, and Pax5 (3). During the GC reaction B cells have a high
replication rate that couples with genome-wide demethylation.
DNMTs and TET enzymes are responsible for the respective
incorporation and removal of methyl groups to cytosines. On the
other hand, passive loss of DNA methylation in heterochromatic
late replication regions is achieved by DNA replication and
high proliferative rates (3, 51). Division-dependent epigenomic
remodeling and DNA demethylation has been studied in the
terminal differentiation of B cells into plasma cells, highlighting
the importance of demethylation, increased gene expression
and the fact that B cells require a number of cell divisions to
successfully reach the stage of plasma cells driven by a specific
transcriptional program (13, 14). Nevertheless, the so-called
epigenetic memory maintains transcription factor activity in
more differentiated cell subsets, which, in memory and plasma
B cells, drives their long lifespan and ability to generate specific
antigenic responses (12, 27). Therefore, subtle alterations in
epigenetic marks could have a critical impact in memory
transcription profiles.
In CVID patients, six out of nine (66%) selected CpGs
(AICDA, BCL6, FOXO, AKT1, NFKB2, and STAT3) showed
significant hypermethylation in switched memory B cells in
comparison to healthy donors. Impaired demethylation is
therefore not detected for all CpGs studied, suggesting that this
status is not related to an unspecific drift or generalized aberrancy
of circulating cells.
AICDA is a key regulator of terminal B cell activation.
In naïve B cells AICDA is epigenetically repressed, and the
progression to the next maturation stages associates with
promoter demethylation, together with permissive histone
modifications that favor an open chromatin state (10). AICDA
hypomethylation and expression has been shown to be essential
for CSR and SHM (6, 11, 52). Our results suggest that deregulated
epigenetic control of AICDA during the GC reaction may play
a role in the defective establishment of a post-germinal center
B cell compartment in CVID. First, we observed impaired
AICDA demethylation in switched memory B cells from CVID
patients, in which this impairment correlated with the reduced
number of switched memory B cells in CVID patients. This
correlation was also observed for reduced unswitched B cells,
which is in agreement with a role of AID in unswitched
memory B cells that experienced less extensive but evident SHM.
Therefore, as expected, a significant impact in reduced SHM is
observed in both switched and unswitched memory B cells from
CVID patients.
Regarding the possible impaired mechanism by which AICDA
is not experiencing demethylation in CVID memory B cells,
we observed how the proliferative rate, measured by the KREC
assay, is lower in those switched memory B cells with the highest
methylation levels for AICDA. Defective passive demethylation
during late B-cell differentiation could therefore be related to
proliferative rates in CVID B cells. In this respect, the total
number of cell divisions in CVID memory B cells is similar
to healthy counterparts, suggesting that a gross proliferative
defect is not implied in the reduced demethylation. Intriguingly,
naïve B cells from CVID patients accumulated significant higher
mean number of cell divisions than controls. This allows the
speculation that memory B cells from CVID patients might have
experienced reduced number of cell divisions in the transition
from the naïve to thememory stage during GC reaction, although
this cannot be formally proven at single cell level. A plausible
explanation for defective demethylation in memory B cells
from CVID patients could be that impaired upstream activation
precludes division coupled epigenomic remodeling.
An alternative explanation is that active demethylation
mechanisms might be defective in CVID patients. Although, it is
still a vivid debate, a role for AICDA in active demethylation has
been explored in the context of B cell activation (44). Domínguez
et al. investigated the epigenetic function of AICDA in germinal
center B cells in AID deficient (Aicda−/−) mice, implicating
AID in the loss of DNA methylation in targeted specific loci in
germinal center B cells. AID dependent demethylation is coupled
to the rate of SHM. However, residual hypomethylation was
still observed in Aicda−/− mice, suggesting other mechanisms
involved in DNA demethylation, such as TET enzymes or
passive demethylation by high proliferation rates. Therefore, the
impaired demethylation of AICDA observed in CVID patients
could be contributing not only to the decreased SHM in memory
B cells but to further demethylation processes.
Other relevant genes for B cell differentiation showed
impaired DNA demethylation and might impact on B cell
deregulation presented in CVID patients. BCL6, the master
regulator for GC reaction to repress genes implicated in
B cell activation, is a negative regulator of cell cycle and
inhibits B cell differentiation to memory and plasma cells
by Blimp-1 repression (42, 53). BCL6 is regulated by post
translational modifications (44) and it has been reported to
interact with histone deacetylases HDAC1 (10) to potentially
repress transcription. In all, this reflects the interplay between
the key transcription factors and the epigenetic machinery during
B cell differentiation (6, 53, 54). Interestingly, CVID patients
with normal memory B cell phenotype that showed similar
methylation patterns as controls for most CpGs continued to
display impaired demethylation of the BCL6 gene, indicating
that altered methylation in some patients could contribute to
impaired plasma cell differentiation.
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Significant hypermethylation of CpGs near two other relevant
genes promoters, for B cell signaling and maturation, STAT3 and
NFκB2, was also identified. STAT3 has a relevant role in IL10
and IL21 signal transduction for naive B cell differentiation to
memory and plasma cells (37, 38). NFκB2 murine knockdown
and mutant models show altered structures in lymph nodes and
spleen with dysfunctional germinal centers, as well as impaired
plasma cell formation (55, 56). Furthermore, germline mutations
in NFκB2 have been associated with CVID pathogenesis (57).
All CpG methylation analyses so far showed similar patterns
of methylation in CVID and control naïve B cells. We have
found a first exception for a CpG related to FOXO, which was
hypomethylated in CVID naïve B cells. FOXO transcription
factors regulate genes with functions in apoptosis, cell cycle,
longevity and DNA repair (30, 31). The axis PI3K-Akt-Foxo1
and the strict regulation of this pathway is relevant for
B cell survival, proliferation, activation and terminal B cell
differentiation (32, 33, 58).
Our new results of increased selective hypermethylation
in functionally relevant genes for terminal B cell maturation
reinforce the hypothesis of impaired demethylation as a
mechanism affecting this process in CVID. Interestingly, gain
of methylation was also originally reported in ICF syndrome,
where hypermethylation was observed in genes associated
with B cell differentiation despite a genome-wide loss of
methylation attributed to a DNMT3 mutation. ICF syndrome
patients can present a component of primary immunodeficiency
immunologically similar to CVID (59).
In summary, our study suggests that impaired demethylation
in the transition from naïve to memory B cells in CpGs at genes
implicated in B cell signaling and survival (STAT3, AKT1, FOXO,
and NFKB2), and at genes required for the GC reaction (AICDA
and BCL6) might contribute to the terminal B cell defect in
CVID patients. The intensity of impairment in demethylation
is associated with the reduction of memory B cells in CVID
patients. CVID is a complex disease not associated to single
gene defects in many patients. Several accumulative B cells
specific defects might be contributing to its pathogenesis. The
potential implication of altered epigenetic control of terminal B
lymphocyte differentiation is only at the dawn of its definition
in CVID. Now we present novel insights that point out the
possible implication of both passive, due to reduced proliferation
rate between naive and switched memory B cells, and active
demethylationmechanisms involvingAICDA in the pathogenesis
of CVID. Based on our data, we cannot conclude if defective
demethylation is a primary pathogenic mechanism disturbing
memory B cell differentiation, or a downstream contributing
consequence of impaired activation or signaling in CVID
memory B cells.
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(BAFFR), PI3K activation pathway (AKT1 and FOXO), NFκB canonical pathway
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